Twinbeech Capital LP Sage Therapeutics, Inc. Transaction History
Twinbeech Capital LP
- $4.91 Billion
- Q2 2024
A detailed history of Twinbeech Capital LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 38,114 shares of SAGE stock, worth $265,273. This represents 0.01% of its overall portfolio holdings.
Number of Shares
38,114
Previous 105,406
63.84%
Holding current value
$265,273
Previous $1.98 Million
79.09%
% of portfolio
0.01%
Previous 0.04%
Shares
10 transactions
Others Institutions Holding SAGE
# of Institutions
217Shares Held
48.2MCall Options Held
854KPut Options Held
195K-
Vanguard Group Inc Valley Forge, PA6.42MShares$44.7 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$38.1 Million0.99% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$36.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$31.1 Million0.81% of portfolio
-
State Street Corp Boston, MA2.47MShares$17.2 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $414M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...